Olezarsen Reduces Triglycerides, Acute Pancreatitis Events

Why It Matters

The data demonstrate that aggressive triglyceride reduction can translate into tangible clinical benefit, positioning olezarsen as a potential new standard for patients at risk of pancreatitis and cardiovascular complications.

Key Takeaways

• Olezarsen 80 mg cut triglycerides 65.5% at six months
• Acute pancreatitis risk fell 85% with olezarsen versus placebo
• 85% of patients reached triglycerides below 880 mg/dL on treatment
• FDA approved olezarsen for familial chylomicronemia, not severe hypertriglyceridemia

Pulse Analysis

Severe hypertriglyceridemia, defined by triglyceride levels above 880 mg/dL, has long been a therapeutic blind spot. Patients face a heightened risk of acute pancreatitis and residual cardiovascular danger despite conventional fibrates or omega‑3 fatty acids, which only modestly lower triglycerides. Olezarsen, an antisense oligonucleotide that silences apolipoprotein C‑III, targets the root of triglyceride overproduction, offering a mechanistic advantage over older agents.

The pooled analysis of the CORE‑TIMI 72a and 72b trials revealed striking efficacy. At six months, the 50 mg dose reduced triglycerides by 58.8% and the 80 mg dose by 65.5%, with over 85% of participants achieving levels below the 880 mg/dL threshold. More importantly, the incidence of acute pancreatitis dropped to 15% of the placebo rate, translating to a number needed to treat of nine over twelve months. These outcomes eclipse the modest benefits seen with fibrates and omega‑3s, which have not demonstrated pancreatitis prevention in randomized settings.

For the U.S. market, the results could reshape treatment algorithms. Although olezarsen received FDA approval in 2024 for familial chylomicronemia syndrome, its label does not yet cover severe hypertriglyceridemia. The compelling efficacy and safety data may accelerate a supplemental indication request, offering clinicians a potent tool to mitigate pancreatitis risk and improve lipid profiles. Future research will likely explore long‑term cardiovascular outcomes and real‑world adoption, potentially establishing olezarsen as a cornerstone therapy for a patient segment that has been historically underserved.